J.P. Morgan Raising Estimates on Amgen

J.P. Morgan Chase & Co. is out with a research report on Amgen AMGN and it has an Overweight rating and a $70 price target on shares. In a note to clients, J.P. Morgan Chase & Co. writes, "We have increased our 3Q EPS estimate to $1.31 from $1.30 (cons: $1.29), though we are conservatively below the street on EPO sales ($7M below at $516M) and Neupogen/Neulasta sales. The key to the stock should be upside from the Xgeva/Prolia franchise (JPMe: $180M; cons: $152M) and initial signals of a stabilizing EPO / Aranesp franchise with an eye towards 2012." Shares of AMGN closed at $56.98 yesterday, up 34 cents.